rs12752133 — GBA

GBA rs12752133 — The Intronic Lysosomal Signal for REM Sleep Behavior Disorder

Deep inside your cells, lysosomes serve as the recycling centres responsible for breaking down worn-out proteins, lipids, and cellular debris. One enzyme is central to this process in neurons: glucocerebrosidase (GCase)¹¹ glucocerebrosidase (GCase)
encoded by the GBA1 gene, GCase converts glucosylceramide into glucose and ceramide — a routine lysosomal step whose impairment has outsized consequences for brain health. GBA variants are already established as the strongest known genetic risk factor for Parkinson's disease, and rs12752133 represents an independent intronic signal at the same locus with a large, replicated effect on the earliest detectable stage of this disease spectrum: REM sleep behavior disorder (RBD).

RBD — in which people physically act out vivid dreams during REM sleep — is not merely a sleep disorder. It is now recognised as a prodromal synucleinopathy marker, typically preceding Parkinson's disease diagnosis by a decade or more. Identifying your genetic risk profile at the GBA locus while still in this pre-motor window is the most actionable time to intervene.

The Mechanism

rs12752133 is an intronic variant located 94 nucleotides downstream of exon 11 in GBA1, at chromosomal position chr1:155,235,587 (GRCh38). The GBA gene is transcribed from the minus strand, so the plus-strand C→T change corresponds to a G→A transition on the coding strand within intron 11. The precise molecular mechanism by which this intronic position modulates disease risk is not yet fully characterized, but the leading hypothesis is that it alters pre-mRNA splicing efficiency or GBA1 expression levels, either independently or by influencing the regulatory architecture of the broader GBA1-GBAP1 locus region.

The downstream consequence is the same as for other GBA risk variants: reduced glucocerebrosidase activity impairs the autophagy-lysosomal pathway that dopaminergic neurons depend on to degrade misfolded proteins. When GCase activity falls, the glycolipid glucosylceramide accumulates. Glucosylceramide directly stabilises alpha-synuclein oligomers — the toxic species that seed Lewy body formation — while simultaneously inhibiting GCase further, creating a self-reinforcing vicious cycle²² self-reinforcing vicious cycle
Moors et al. Mov Disord 2016: lysosomal dysfunction and alpha-synuclein aggregation in post-mortem GBA-PD brain tissue between lysosomal failure and protein aggregation.

Importantly, rs12752133 and the N409S coding variant (rs76763715) are independent signals at the GBA locus — they sit 256 bp apart, likely in different functional elements of the gene, and their risk contributions are statistically separable in GWAS analysis.

The Evidence

The clearest evidence for rs12752133 comes from the largest genome-wide association study of REM sleep behavior disorder conducted to date³³ the largest genome-wide association study of REM sleep behavior disorder conducted to date
Krohn et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nature Communications, 2022. This meta-analysis enrolled 2,843 RBD cases and 139,636 controls, identifying five genome-wide significant loci: SNCA, GBA, TMEM175, INPP5F, and SCARB2. At the GBA locus, rs12752133-T reached p=5×10⁻¹⁴ with an odds ratio of 2.09 (95% CI 1.73–2.54) — a very large effect size for a GWAS finding. The GBA and TMEM175 loci were notable for being shared across all three main synucleinopathies studied: isolated RBD, Parkinson's disease with probable RBD, and Parkinson's disease without RBD, suggesting a fundamental biological role in the synucleinopathy continuum.

The broader case for GBA as the most consequential Parkinson's disease risk gene was established by the landmark multicenter NEJM study⁴⁴ the landmark multicenter NEJM study
Sidransky et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. NEJM, 2009, which analyzed 5,691 PD patients and 4,898 controls across 16 international centers and found an overall OR of 5.43 for any GBA mutation. The Nalls et al. 2019 meta-analysis⁵⁵ The Nalls et al. 2019 meta-analysis
Nalls et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease. Lancet Neurology, 2019 — spanning 37,688 cases and 1.4 million controls — confirmed GBA as one of 78 replicated genomic regions, underscoring the locus's biological centrality to PD pathogenesis.

Practical Actions

For T-allele carriers, the GBA mechanism suggests three actionable priorities: supporting lysosomal function and GCase activity, monitoring for prodromal RBD before motor symptoms appear, and avoiding environmental neurotoxins that compound dopaminergic vulnerability. The ambroxol pharmacological chaperone approach — currently in Phase 2 clinical trials targeting GBA-related neurodegeneration — represents the most mechanistically direct intervention available. Ambroxol binds misfolded GCase in the endoplasmic reticulum, stabilising its conformation to increase lysosomal delivery and enzyme activity; preclinical and open-label human data confirm it increases GCase activity and reduces CSF alpha-synuclein levels in GBA variant carriers.

Interactions

rs12752133 and the coding N409S variant (rs76763715) are independent signals at the GBA locus. Carriers of both may face compound impairment of GCase expression (via the intronic regulatory effect of rs12752133-T) and GCase protein folding (via the missense effect of N409S), potentially compounding lysosomal failure beyond either variant alone. This is a compound action candidate.

Within the broader synucleinopathy picture, GBA risk alleles interact with SNCA variants (rs356219, rs356182, rs2736990) — elevated alpha-synuclein from SNCA and impaired lysosomal clearance from GBA represent two independent drivers of Lewy body pathology converging on the same dopaminergic neuron population. The TMEM175 lysosomal potassium channel variant (rs76904798) is another locus identified in the same RBD GWAS that impairs lysosomal acidification — a second lysosomal mechanism compound action candidate alongside GBA.